New Findings for Novel Pan-Genotypic HCV Regimen in Phase 3 Study

The primary endpoint was the percentage of patients achieving sustained virologic response at 12 weeks post-treatment
The primary endpoint was the percentage of patients achieving sustained virologic response at 12 weeks post-treatment

AbbVie announced new findings from the EXPEDITION-1 study, a Phase 3 trial evaluating the efficacy and safety of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C virus (HCV) infection in patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A). Data will be presented at The International Liver Congress (ILC) 2017 in Amsterdam, The Netherlands.

EXPEDITION-1 is a single-arm, multicenter, open-label trial of 12 weeks treatment with G/P, without ribavirin, in 146 treatment-naïve and treatment-experienced adults with GT1, 2, 4, 5 or 6 chronic HCV infection and compensated cirrhosis. Patients with specific virus strains associated with resistance or with a high quantity of viral load at baseline were not excluded from the study. The primary endpoint was the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12). 

New findings from EXPEDITION-1 showed that 99% of HCV infected patients with GT 1, 2, 4, 5 or 6 and compensated cirrhosis achieved SVR12 after 12 weeks of G/P treatment. Only one patient with a GT1a infection experienced relapse. These high SVR12 rates were observed with G/P treatment without ribavirin. Additionally, G/P was found to be well-tolerated, with mild adverse events (AEs) and no drug-related discontinuations. Fatigue and headache were the most common AEs and no patients experienced ALT elevations ≥Grade 3.

Additional study data in specific populations with treatment challenges, including patients with chronic kidney disease, HIV-1 co-infection, post liver and renal transplant patients and in patients who did not achieve SVR12 with previous direct-acting antiviral (DAA) treatment, will also be presented.

G/P is an investigational, fixed-dose (300/120mg), once-daily, pan-genotypic regimen consisting of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, NS5A inhibitor. The FDA has recently granted Priority Review to its NDA in February 2017.

For more information call (800) 633-9110 or visit Abbvie.com.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs